跳至主要内容
临床试验/NCT03272126
NCT03272126已完成3 期

Importance of Dosing Regimen for the Effect of Vitamin D Supplementation

University of Tromso1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2017年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
61
试验地点
1
主要终点
Hepcidin change

研究概览

简要总结

Vitamin D is a hormone with effects not only on the skeleton, but on most tissues in the body. Lack of vitamin D is associated with cardio-vascular disease (CVD), type 2 diabetes, cancer, infectious and immunological diseases, as well as risk factors for these diseases. However, intervention studies with vitamin D have been inconclusive regarding diseases and risk factors. This could be due to inclusion of subjects already vitamin D sufficient, and short and underpowered studies. In addition, there are indications that the dosing regimens may be important, so that daily doses with vitamin D are more efficient than intermittent doses, which so far have been generally used. This could be related to the concentration of circulating and thereby intracellular vitamin D concentrations, which probably is dependent on daily vitamin D doses. This will be tested in the present study where 60 subjects will be randomized to vitamin D 160 000 once, vitamin D 4000 IU/day, or placebo for four weeks. The primary endpoints will be effects on serum hepcidin and plasma cathelicidin after 4 weeks, with effects on serum PTH, RNA expression and microRNA in peripheral blood, telomerase activity in peripheral blood mononuclear cells and the ration between serum 1,25(OH)2D and 24,25(OH)2D as secondary endpoints.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females 20 - 70 years
  • 20 kg/m2 > BMI < 35 kg/m2
  • systolic BP < 175 mmHg, diastolic BP < 105 mmHg
  • Serum 25(OH)D level < 50 nmol/L. Serum 25(OH)D < 50 nmol/L is considered as vitamin D deficiency, and accordingly, effects of vitamin D supplementation will be easier to detect than if the included subjects were vitamin D sufficient.
  • Hgb, SR, CRP, creatinine < 130 umol/L in males, < 120 umol/L in females, calcium, FT4 and TSH within the normal reference range; ASAT < 90 mU/L ALAT < 140 U/L, HbA1c < 6.6 %
  • The subjects must agree not to take any vitamin D supplementation, including cod liver oil or "mølje", use solarium or go on sunny vacation during the intervention period.

排除标准

  • subjects allergic to peanuts
  • subjects with primary hyperparathyroidism
  • granulomatous diseases (sarcoidosis, tuberculosis, Wegner's granulomatosis)
  • renal stones the last five years
  • subjects seriously ill (or with chronic disease) and unfit for participation in the study (as judged by one of the study doctors)
  • subjects using vitamin D supplements exceeding 800 IU per day or active vitamin D drugs (Rocaltrol or Etalpha)
  • pregnancy

研究组 & 干预措施

vitamin D bolus

Experimental

vitamin D 160 000 IU given as bolus

干预措施: Vitamin D (Drug)

vitamin D daily

Experimental

vitamin D 4000 IU daily for 28 days

干预措施: Vitamin D (Drug)

placebo

Placebo Comparator

identical looking as vitamin d

干预措施: Placebo (Drug)

结局指标

主要结局

Hepcidin change

时间窗: 4 weeks

Difference between vitamin D given as a bolus 160 000IU vs 4000 IU regarding change in serum hepcidin

次要结局

  • Difference in RNA Expression after 1 month(4 weeks)
  • Difference in telomerase Activity after 1 month(4 weeks)
  • Difference in ratio between 1,24(OH)2D and 24,24(OH)2D after 1 month(4 weeks)
  • Difference in serum PTH after 1 month(4 weeks)
  • Difference in micro RNA Expression after 1 month(4 weeks)
  • Difference in serum cathelicidin after 1 month(4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验